摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-amino-1-β-D-ribofuranosylimidazole-4-carbonitrile | 23192-64-5

中文名称
——
中文别名
——
英文名称
5-amino-1-β-D-ribofuranosylimidazole-4-carbonitrile
英文别名
5-amino-4-cyano-1-(β-D-ribofuranosyl)imidazole;5-amino-1-beta-D-ribofuranosyl-4-cyanoimidazole;5-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]imidazole-4-carbonitrile
5-amino-1-β-D-ribofuranosylimidazole-4-carbonitrile化学式
CAS
23192-64-5
化学式
C9H12N4O4
mdl
——
分子量
240.219
InChiKey
HQUFDEULYSDZNH-JXOAFFINSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -1.3
  • 重原子数:
    17
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.56
  • 拓扑面积:
    138
  • 氢给体数:
    4
  • 氢受体数:
    7

SDS

SDS:9edd426020ea4ae3fc710095a71efbc9
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2
    • 3

反应信息

点击查看最新优质反应信息

文献信息

  • Synthesis and coronary vasodilating activity of 2-substituted adenosines.
    作者:RYUJI MARUMOTO、YOSHIO YOSHIOKA、OSAMU MIYASHITA、SHUNSUKE SHIMA、KINICHI IMAI、KATSUYOSHI KAWAZOE、MIKIO HONJO
    DOI:10.1248/cpb.23.759
    日期:——
    A large scale preparation of 2-haloadenosines (1) was attained by acetylation of 2-haloinosines (3), followed by chlorination and amination. 2-Alkoxyadenosines (5) were prepared in fairly good yields by protection of both 2'- and 3'-hydroxyl groups of 2-chloroadenosine (1a) or 2-chloroinosine (3a), followed by substitution of the chlorine atom with alkoxy group. In the reaction of 1a with sodium alkoxide, there were obtained some oligomers of 5, of which the structures were elucidated. The reaction of 5-amino-4-cyano-1-β-D-ribofuranosylimidazole with carbon disulfide afforded 2, 6-di-mercapto-9-β-D-ribofuranosylpurine (15), which was converted to 2-mercaptoadenosine (14e) and its S-substituted derivatives. 2-Phenylaminoadenosine (29e) was prepared with comparative ease via 2-phenylamino-2', 3', 5'-tri-O-acetylinosine (32), the synthesis of which was effected by acetylation of 2-phenylaminoinosine (30) with acetylchloride in acetic acid. Many 2-substituted adenosines including O-substituted 2-hydroxyadenosines, S-substituted 2-mercaptoadenosines, N2-substituted 2-aminoadenosines, 2-alkyl- and -aryl-adenosines were prepared, among which several compounds were found to have a remarkable coronary vasodilating potency. Compound (29e) showed not only a strong potency, but also a longer duration of the effect than that of 1a. The structure-coronary vasodilating activity relationship was also discussed.
    通过乙酰化2-卤代次黄嘌呤核苷(3)继以氯化和胺化,制得了2-卤代腺嘌呤核苷(1)的大量样品。通过保护2-氯腺嘌呤核苷(la)或2-氯代次黄嘌呤核苷(3a)的2'-和3'-羟基,然后用烷氧基团取代氯原子,制得了收率相当不错的2-烷氧基腺嘌呤核苷(5)。la与烷醇钠反应,得到5的一些寡聚体,其结构已得到阐明。5-氨基-4-氰基-1-β-D-呋喃核糖基咪唑与二硫化碳反应,生成2,6-二巯基-9-β-D-呋喃核糖基嘌呤(15),可转化为2-巯基腺嘌呤核苷(14e)及其S-取代衍生物。2-苯胺基腺嘌呤核苷(29e)通过2-苯胺基-2',3',5'-三-O-乙酰次黄嘌呤核苷(32)比较容易地制得,而32是通过2-苯胺基次黄嘌呤核苷(30)在乙酸中与乙酰氯反应进行乙酰化来合成的。制备了许多2-取代腺嘌呤核苷,包括O-取代2-羟基腺嘌呤核苷、S-取代2-巯基腺嘌呤核苷、N2-取代2-氨基腺嘌呤核苷、2-烷基和芳基腺嘌呤核苷,其中发现几种化合物具有显著的冠状血管舒张活性。化合物(29e)不仅显示了强大的活性,而且其效果的持续时间比la更长。还讨论了结构-冠状血管舒张活性关系。
  • Novel adenosine derivatives and pharmaceutical composition containing
    申请人:Nippon Zoki Pharmaceutical Co., Ltd.
    公开号:US04843066A1
    公开(公告)日:1989-06-27
    Novel adenosine compounds of the formula (I): ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 are hydrogen or a lower alkyl group; X is hydrogen, a lower alkyl group, an amino group or halogen; and Y is hydrogen or a lower alkyl group, exhibit utility as antihypertensive agents.
    新型腺苷化合物的化学式(I):##STR1## 其中 R.sub.1、R.sub.2 和 R.sub.3 为氢或较低的烷基基团;X 为氢、较低的烷基基团、氨基或卤素;Y 为氢或较低的烷基基团,作为降压药物具有实用性。
  • Purines. LXIV. Syntheses of 9-Methyl-2-azaadenine 1-Oxide, Its O-Methyl Derivative, and 1-Substituted 5-Azidoimidazole-4-carboxamides.
    作者:Tohru SAITO、Yayoi ASAHI、Satoshi NAKAJIMA、Tozo FUJII
    DOI:10.1248/cpb.42.2263
    日期:——
    Diazotization of 5-amino-N'-methoxy-1-methylimidazole-4-carboxamidine (4a) with NaNO2 in 1N aqueous HCl was found to give the 1-methoxy-2-azaadenine derivative 8a·HI, which produced 5-azido-1-methylimidazole-4-carbonitrile (5a) on treatment with aqueous Na2CO3. The ribosyl analogue 5b, obtained from the riboside 4b by similar diazotization, was utilized for the synthesis of 5-azido-1-β-D-ribofuranosylimidazole-4-carboxamide (9b), a novel AICA riboside analogue. On heating in HCONMe2 at 70°C for 10min, 8a·HI yielded the 1-N-oxide 7a. Several reactions to transform the functional groups in 5a were also investigated.
    5-氨基-N'-甲氧基-1-甲基咪唑啉-4-甲脒(4a)在1N水合HCl中用NaNO2进行重氮化反应,得到1-甲氧基-2-氮杂腺嘌呤衍生物8a·HI,该物质在处理后与水合Na2CO3反应生成5-叠氮-1-甲基咪唑啉-4-氰化物(5a)。通过类似的重氮化反应从核苷4b得到的核糖类似物5b,被用于合成5-叠氮-1-β-D-呋喃核糖基咪唑啉-4-羧酰胺(9b),这是一种新颖的AICA核苷类似物。在HCONMe2中加热至70°C并保持10分钟,8a·HI生成1-N-氧化物7a。还研究了几种转化5a中功能团的反应。
  • Synthesis of 2-phenylaminoadenosine from imidazole nucleosides.
    作者:KIYOSHI OMURA、RYUJI MARUMOTO、YOSHIYASU FURUKAWA
    DOI:10.1248/cpb.29.1870
    日期:——
    Three methods for the synthesis of 2-phenylaminoadenosine (1, CV-1808), a potent coronary vasodilator with prolonged action, were exploited. 1) The reaction of 5-amino-4-cyano-1-(β-D-ribofuranosyl) imidazole (7) with phenyl isothiocyanate gave 7-imino-5-phenylamino-3-(β-D-ribofuranosyl) imidazo [4, 5-d] [1, 3]-thiazine (11), which, on alkaline treatment, rearranged to 6-mercapto-2-phenylamino-9-(β-D-ribofuranosyl) purine (12). On methylation, 12 gave the 6-methylmercapto derivative (14), which was converted to 1 by treatment with ammonia. 2) 5-Amino-4-cyano-1-(β-D-ribofuranosyl) imidazole (7) reacted with phenyl cyanamide in methanolic ammonia, giving 1 and 2-aminoadenosine as a by-product. 3) Ethyl 5-amino-1-(β-D-ribofuranosyl)-4-carboximidate (21b) was directly obtained by treatment of 5-amino-1-(2, 3, 5-tri-O-propionyl-β-D-ribofuranosyl) imidazole-4-carboxamide (4) with Meerwein's reagent followed by deacylation, and this was led to 1 by the reaction with phenyl cyanamide.
    开发了三种合成2-苯胺腺苷(1,CV-1808)的方法,这是一种具有持久作用的强效冠状动脉扩张剂。1)5-氨基-4-氰基-1-(β-D-呋喃核糖基)咪唑(7)与苯基异硫氰酸酯反应,生成7-亚氨基-5-苯胺基-3-(β-D-呋喃核糖基)咪唑并[4,5-d][1,3]噻嗪(11),后者经碱性处理后重排为6-巯基-2-苯胺基-9-(β-D-呋喃核糖基)嘌呤(12)。甲基化后,12生成6-甲硫基衍生物(14),通过氨处理转化为1。2)5-氨基-4-氰基-1-(β-D-呋喃核糖基)咪唑(7)在甲醇氨中与苯基氰胺反应,生成1和2-氨基腺苷作为副产品。3)通过5-氨基-1-(2,3,5-三-O-丙酰基-β-D-呋喃核糖基)咪唑-4-羧酰胺(4)与Meerwein试剂处理后去酰化,直接得到乙基5-氨基-1-(β-D-呋喃核糖基)-4-羧基咪唑盐(21b),然后通过与苯基氰胺反应生成1。
  • Synthesis of 2-substituted adenine-arabinosides and related compounds from 5-amino-4-cyano-1-(.BETA.-d-ribofuranosyl)imidazole.
    作者:Yoshiko SATO、Tokumi MARUYAMA、Mikio HONJO
    DOI:10.1248/cpb.37.1604
    日期:——
    Triflation of the N5-benzylidene-3', 5'-O-silyl protected 5-amino-4-cyano-1-(β-D-ribofuranosyl)imidazole (AICN-riboside) (IIb), followed by nucleophilic displacement with OAc- and N3-provided the corresponding 2'(S)-substituted derivatives (VIIa, VIIb). Deprotection of the silyl and benzylidene groups of VIIa, followed by hydrolysis of the acetyl group gave AICN-arabinoside (IXc). Reaction of IXc with alkyl, aryl and aralkyl nitriles afforded the corresponding 2-substituted adenine-arabinosides (XIa-e). The 2'-azido (Xa) and 2'-amino (Xb) analogs of XIa were similarly prepared.
    N5-苄亚基-3', 5'-O-硅保护5-氨基-4-氰基-1-(β-D-核糖基)咪唑(AICN-核苷)(IIb)的三氟化反应,随后与OAc和N3进行亲核取代,得到相应的2'(S)-取代衍生物(VIIa,VIIb)。去保护VIIa中的硅基和苄亚基,随后水解乙酰基,得到AICN-阿拉伯糖苷(IXc)。IXc与烷基、芳基和芳烷基氰化物反应,得到相应的2-取代腺苷-阿拉伯糖苷(XIa-e)。XIa的2'-叠氮(Xa)和2'-氨基(Xb)类似物也以类似方式制备。
查看更多

同类化合物

阿卡地新 咪唑立宾 5'-单磷酸酯 咪唑立宾 [(2R,3S,4R,5R)-5-[4-氨基甲酰-5-[[(3R,4R)-3,4-二羟基-2-氧代-5-膦酰氧基戊基]亚氨基甲基氨基]咪唑-1-基]-3,4-二羟基四氢呋喃-2-基]磷酸二氢甲酯 N-[5-氨基-1-(BETA-D-呋喃核糖基)咪唑-4-羰基]-L-天冬氨酸 5-碘-1-(2’,3’,5’-三-O-乙酰基-beta-D-呋喃核糖基)-咪唑并-4-甲腈 5-甲酰氨基咪唑-4-甲酰胺核苷酸 5-氯-1-[3,4-二羟基-5-(羟基甲基)四氢呋喃-2-基]咪唑-4-甲酰胺 5-氨基-4-咪唑甲酰胺核糖甙 5'-三磷酸酯 5-氨基-1-(2-O,3-O,5-O-三乙酰基-beta-D-呋喃核糖基)-1H-咪唑-4-甲酰胺 5-氨基-1-(2,7-二羟基-2-氧代四氢-4H-呋喃并[3,2-d][1,3,2]二氧杂环己膦烷-6-基)-1H-咪唑-4-甲酰胺 5-乙炔基-1-呋喃核糖基咪唑-4-甲酰胺 4-(羧甲基)-1-(beta-D-呋喃核糖基)-1H-咪唑 2-硝基-1-beta-D-呋喃核糖基-1H-咪唑 1-alpha-D-阿拉伯呋喃糖基-2-硝基-1H-咪唑 1-(alpha-D-阿拉伯呋喃糖基)-1H-咪唑-2-胺 (2S)-2-[[5-氨基-1-[(2R,3R,4S,5R)-3,4-二羟基-5-(膦酰氧基甲基)四氢呋喃-2-基]咪唑-4-羰基]氨基]丁二酸 (2R)-2-环己基-2-羟基-2-苯基乙酸 (1-羟基乙基)-5-甲基-1-beta-呋喃核糖基咪唑 5-amino-1-(β-D-ribofuranosyl)-4-(5-propyl-1,2,4-oxadiazol-3-yl)imidazole 5-amino-1-(β-D-ribofuranosyl)-4-(5-phenyl-1,2,4-oxadiazol-3-yl)imidazole 5-amino-1-(β-D-ribofuranosyl)-4-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]imidazole 5-amino-1-(β-D-ribofuranosyl)-4-(5-ethyl-1,2,4-oxadiazol-3-yl)imidazole 5-amino-1-(β-D-ribofuranosyl)-4-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]imidazole 5-[1-(Dimethylamino)ethylideneamino]-1-[2,3-O-(1-methylethylidene)-β-D-ribofuranosyl]-imidazole-4-carbonitrile 1-(2',3',5'-tri-O-benzoyl-β-D-ribofuranosyl)-4-(3-ureidophenyl)imidazole 5-amino-2-(4-fluorophenyl)-1-β-D-ribofuranosylimidazole-4-carboxamide 5-amino-2-(3-chlorophenyl)-1-β-D-ribofuranosylimidazole-4-carboxamide 5-amino-2-(4-methoxyphenyl)-1-β-D-ribofuranosylimidazole-4-carboxamide 5-amino-2-(2-phenylvinyl)-1-β-D-ribofuranosylimidazole-4-carboxamide 5-amino-2-phenyl-1-β-D-ribofuranosylimidazole-4-carboxamide 5-amino-2-(2-furyl)-1-β-D-ribofuranosylimidazole-4-carboxamide 5-amino-1-β-D-ribofuranosylimidazole-2-(2-thienyl)-4-carboxamide 5-amino-1-β-D-ribofuranosylimidazole-4-carboxamideoxime hydrochloride acadesine-5’-O-bis(benzoxy-L-alaninyl)phosphate 5-diazonium-1-β-D-ribofuranosyl-1H-imidazole-4-carboxamide 5-amino-1-(3-O-methyl-β-D-ribofuranosyl)imidazole-4-carboxamide 5-amino-1-(3-O-n-butyl-β-D-ribofuranosyl) imidazole-4-carboxamide 5-amino-1-(3-O-ethyl-β-D-ribofuranosyl)-4-imidazole carboxamide 5-amino-1-(2-O-ethyl-β-D-ribofuranosyl)-4-imidazole carboxamide N4-(benzyl) AICAR triphosphate N1-<(β-D-Ribosyl)formimino>-5-aminoimidazole-4-carboxamide ribonucleotide N1-<(5''-Phospho-β-D-ribosyl)formimino>-5-aminoimidazole-4-carboxamide ribonucleoside N1-<(β-D-Ribosyl)formimino>-5-aminoimidazole-4-carboxamide ribonucleoside 2-Benzyl-1-(β-D-ribofuranosyl)imidazol-4,5-dicarboxamid 4-N-[(S)-pyrrolidine-2-carbonyl]amino-1-β-D-ribofuranosylimidazole 5-amino-1-(β-D-ribofuranosyl)-4-(5-pentyl-1,2,4-oxadiazol-3-yl)imidazole 5-amino-1-(β-D-ribofuranosyl)-4-(5-heptyl-1,2,4-oxadiazol-3-yl)imidazole acadesine-5’-O-bis(methoxy-L-alaninyl)phosphate 4,5-dichloro-1-(β-D-ribofuranosyl)imidazole